Drugs / AMG 139
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01258205 | Feb 2011 → Feb 2015 | Crohn disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01094093 | Apr 2010 → Jul 2011 | psoriasis | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01094093 ↗ |
| Route | Intravenous | “The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and...” NCT01094093 ↗ |
| Route | Subcutaneous | “The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and...” NCT01094093 ↗ |